Perrigo Company PRGO today announced that it has received final approval from the U.S.
Food and Drug Administration for its abbreviated new drug application (ANDA)
for calcium acetate capsules, the generic equivalent of Phoslo(R) Gelcaps.
Perrigo was previously in patent litigation over this product with the brand
and the litigation settled in late 2011. The terms of the settlement are
confidential.
Gelcaps annual brand and equivalent generics sales were approximately $95
million, as measured by Wolters Kluwer Health.
Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This product
is another example of Perrigo's commitment to expand our portfolio and bring
new products to market. This is another demonstration of our strategy to
provide more affordable, high quality healthcare products to patients."
Perrigo Company is a leading global healthcare supplier that develops,
manufactures and distributes OTC and generic prescription (Rx)
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in